NEW YORK (GenomeWeb News) – Biotec Pharmacon today announced it has reached a new non-exclusive deal with Affymetrix for the distribution of ArcticZymes' shrimp alkaline phosphatase (SAP).
ArcticZymes is a subsidiary of Biotec Pharmacon. Affy previously had the exclusive distribution rights to SAP. The new agreement provides Affy with a long-term supply of SAP at "competitive prices" and non-exclusive rights to market, distribute, and sell the product by itself or in combination with other products for life science and diagnostic applications, Biotec said.
The new deal took effect on Sept. 23, and runs through December 2017. Financial and other terms of the agreement were not disclosed.
According to Jan Buch Anderson, managing director of Norway-based ArcticZymes, SAP remains the firm's best-selling product and provides the majority of its sales.
"We are currently building our organization and increasing our sales and marketing capabilities, and it has been very important for us to gain control over the commercial development of our SAP enzyme," he said. "Hopefully this will increase our sales and also make our revenue and earnings less volatile."